Open-label, Randomized, Crossover Study to Prove Bioequivalence Between Opxion (Levonorgestrel 0.75 mg From Bayer de Mexico) and Postday (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers.

Trial Profile

Open-label, Randomized, Crossover Study to Prove Bioequivalence Between Opxion (Levonorgestrel 0.75 mg From Bayer de Mexico) and Postday (Levonorgestrel 0.75 mg From Investigacion Farmaceutica), in Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2012

At a glance

  • Drugs Levonorgestrel (Primary)
  • Indications Pregnancy
  • Focus Pharmacokinetics
  • Acronyms LEVEQ-2
  • Sponsors Bayer
  • Most Recent Events

    • 05 Apr 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top